AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Both stocks have grabbed plenty of headlines over the past year.

2 Pharma Stocks You Can Buy and Hold for the Next Decade

Abbott Labs

Alexandria Real Estate Equities

They offer products that their customers absolutely can't do without, and they also pay dividends.

Got $3,000? Keep It Safe With These 3 Healthcare Stocks

AstraZeneca's (AZN) phase III studies evaluating its investigational inhaler PT027 for asthma meets primary endpoints.

AstraZeneca (AZN) Asthma Candidate Meets Primary Study Goals

Johnson & Johnson

Moderna

Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.

Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?

It is unnecessary to give vaccine boosters to everyone, according to Prof Dame Sarah Gilbert, the scientist behind the Oxford/AstraZeneca vaccine. Gilbert told the Telegraph that some vulnerable groups would need boosters "But I don't think we need to boost everybody.

Covid booster jab not needed for everyone, says AstraZeneca vaccine creator

POSEIDON Phase 3 trial results showed AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy, extended survival in lung cancer patients. The combo therapy topped overall survival (OS) and progression-free survival (PFS), chemotherapy alone in 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).

AstraZeneca's Imfinzi / Tremelimumab Combo Regime Shows Survival Benefit In Lung Cancer Settings

There's at least a "reasonable possibility" AstraZeneca's AZN, -2.26% Vaxzevria COVID-19 vaccine causes Guillain-Barré syndrome, a serious nerve inflammation which may cause temporary loss of feeling and movement and difficulty breathing, the European Medicines Agency said. The regulator called the frequency "very rare" -- as in less than 1 in 10,000 -- as it recommended GBS should be added as a side effect to the product information.

AstraZeneca COVID-19 vaccine may trigger 'very rare' nerve disease, European regulator says

Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of albuterol and budesonide developed by AstraZeneca Plc (NASDAQ: AZN) and Avillion.

AstraZeneca's Two Asthma Trials Meet Primary Endpoints

AstraZeneca PLC has unveiled positive results from two final-stage clinical trials of its asthma treatment candidate, PT027. The drug met all primary goals, demonstrating significant benefits compared to the individual components of the commonly used albuterol.

AstraZeneca asthma candidate passes clinical trials with flying colours

The incidence of the side effect remains extremely rare with only 833 cases being reported worldwide from about 592 million administered doses of the AstraZeneca vaccine.

European Medicines Agency Lists Nerve Disorder As “Very Rare” Side Effect Of AstraZeneca Covid-19 Vaccine

AstraZeneca PLC's chief executive has said that caution needs to exercised over booster jabs for people in the UK as it might add an unnecessary burden in the NHS. A decision on whether to rollout third doses for the UK population is imminent with the  Joint Committee on Vaccination and Immunisation (JCVI) waiting on results from a study in Southampton that has several different booster vaccines.

AstraZeneca boss says booster jab might be unnecessary

Roche Holding AG

Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage.

4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam

AstraZeneca's (AZN) Ultomiris receives expanded approval in the EU to treat children and adolescents with PNH, a rare disease.

AstraZeneca's (AZN) Ultomiris Gets EU Nod for Rare Disease in Kids

Thermo Fisher Scientific

Thermo Fisher's (TMO) new collaboration with AstraZeneca is intended to speed up development and introduction of targeted precision medicine therapies for patients.

Thermo Fisher (TMO)-AstraZeneca to Co-Develop NGS-Based CDx

The pharma giant recently received approval to market Forxiga as a treatment for chronic kidney disease patients in Japan.

AstraZeneca Enters Another Major Market With This Indication

The European Commission has approved Alexion's Ultomiris (ravulizumab) paroxysmal nocturnal hemoglobinuria (PNH) in children (with a bodyweight of 10 kg or above) and adolescents. Alexion became a part of AstraZeneca Plc (NASDAQ: AZN) in July.

AstraZeneca's Ultomiris Scores European Nod For Rare Blood Disorder In Kids, Adolescents

AstraZeneca Plc (NASDAQ: AZN) and the European Commission have settled on the delivery of pending COVID-19 vaccine doses by the Company. The agreement ends legal proceedings over the execution of the Advance Purchase Agreement.

AstraZeneca, EU Reach Settlement On COVID-19 Vaccine Delivery

AstraZeneca PLC (LSE:AZN) and Oxford University's Covid-19 vaccine might be the key to developing a way to help prevent cancer, new research has suggested. Studies at the Ludwig Institute of Cancer Research in collaboration with Oxford scientists took one of the viral vectors used in the Covid-19 vaccine to treat mice.

AstraZeneca/Oxford vaccine to be trialed as cancer treatment

AstraZeneca PLC and the European Union have reached an agreement on the delivery of outstanding COVID-19 vaccine doses by the pharmaceutical company, which will end the legal dispute between the two parties. A contract between AstraZeneca and the EU, entered into in 2020, estimated the delivery of 300 million vaccine doses by the end of June 2021, but so far, only 100 million doses have been supplied.

AstraZeneca and EU settle dispute over Covid-19 vaccine delivery

AstraZeneca PLC and Oxford University's Covid-19 vaccine might be the key to developing a way to help prevent cancer, new research has suggested. Studies at the Ludwig Institute of Cancer Research in collaboration with Oxford scientists took one of the viral vectors used in the Covid-19 vaccine to treat mice.

AstraZeneca / Oxford vaccine to be trialed as cancer treatment

AstraZeneca and EU settle dispute over COVID-19 vaccine supply

GlaxoSmithKline

GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The study will enroll 4,000 participants and compare the shot to Oxford University - AstraZeneca Plc (NASDAQ: AZN).

Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot

GlaxoSmithKline PLC has started phase III trials of a Covid-19 vaccine that will test itself against rival AstraZeneca PLC's jab. This study will be one of the first global Phase 3 trials to compare two different Covid-19 vaccine candidates said Glaxo, with AstraZeneca/Oxford University's Covid-19 vaccine the active comparator in the trial.

GlaxoSmithKline to test new Covid vaccine against AstraZeneca jab

Biogen

Clovis Oncology

Denali Therapeutics

Eli Lilly

Morphosys AG - ADR

Clovis Oncology Inc. ( CLVS , Financial) and Denali Therapeutics Inc. ( DNLI , Financial) are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would be the most expensive of the pair with a market cap of $6.4 billion, while Clovis is far more digestible with a market value of only $567 million.

Biotech Takeovers Moved at Snail's Pace in 2nd Quarter

Axsome Therapeutics

Nasdaq

Novavax

Pieris Pharma

Cassava Sciences Inc

Seagen

Sanofi

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

Which Biotech Stock Will Shock the Market in 2022?

News for AstraZeneca Stock (AZN)